RH Reports Fourth Quarter and Fiscal Year 2023 Results

3/27/24 4:05:00 PM ET

Other Specialty Stores

Consumer Discretionary

Get the next $RH alert in real time by email

RH (NYSE:RH) has released its financial results for the fourth quarter and fiscal year ended February 3, 2024, in a shareholder letter from Chairman and Chief Executive Officer Gary Friedman, available on the Investor Relations section of its website at ir.rh.com.

As previously announced, RH leadership will host a live conference call and audio webcast at 2:00 pm Pacific Time (5:00 pm Eastern Time) today. The live conference call may be accessed by dialing 800.715.9871 or 646.307.1963 for international callers (passcode: RH call). The call and replay can also be accessed via audio webcast at ir.rh.com.

ABOUT RH

RH (NYSE:RH) is a curator of design, taste and style in the luxury lifestyle market. The Company offers collections through its retail galleries, sourcebooks, and online at RH.com, RHContemporary.com, RHModern.com, RHBabyandChild.com, RHTEEN.com and Waterworks.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240327711716/en/

Get the next $RH alert in real time by email

Date	Price Target	Rating	Analyst
11/13/2024	$253.00	Neutral → Underperform	Exane BNP Paribas
10/21/2024	$430.00	Neutral → Outperform	Wedbush
7/9/2024	$315.00	Buy	Stifel
6/6/2024	$335.00 → $320.00	Market Perform	Telsey Advisory Group
3/28/2024	$285.00 → $335.00	Market Perform	Telsey Advisory Group
12/8/2023	$325.00 → $285.00	Market Perform	Telsey Advisory Group
12/5/2023	$365.00 → $325.00	Market Perform	Telsey Advisory Group
6/29/2023	$300.00	Buy → Hold	Loop Capital

RH Reports Fourth Quarter and Fiscal Year 2023 Results

Chat with this insight

Recent Analyst Ratings for $RH

$RH SEC Filings

SEC Form 144 filed by RH

SEC Form 144 filed by RH

SEC Form 10-Q filed by RH

$RH Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Demilio Mark S was granted 8,000 shares, increasing direct ownership by 198% to 12,047 units (SEC Form 4)

Officer Lee Edward T exercised 2,000 shares at a strike of $101.25 and sold $707,142 worth of shares (2,000 units at $353.57) (SEC Form 4)

Director Demilio Mark S sold $1,025,599 worth of shares (3,000 units at $341.87) (SEC Form 4)

$RH Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

CHAIRMAN & CEO Friedman Gary G bought $9,999,978 worth of shares (46,274 units at $216.10), increasing direct ownership by 1% to 3,351,337 units (SEC Form 4)

$RH Large Ownership Changes

This live feed shows all institutional transactions in real time.

$RH Leadership Updates

Live Leadership Updates

$RH Press Releases

Fastest customizable press release news feed in the world

$RH Financials

Live finance-specific insights

$RH Market Insights

Live Market Insights

Amendment: SEC Form SC 13G/A filed by RH

Amendment: SEC Form SC 13G/A filed by RH

Amendment: SEC Form SC 13G/A filed by RH

RH Announces the Appointment of Jarrett Stuhl as Chief Real Estate & Development Officer

Remitly Appoints Two New Members to its Board of Directors

RH Announces the Opening of RH Raleigh, The Gallery at North Hills

RH Reports Second Quarter Fiscal 2024 Results

RH to Report Second Quarter Fiscal 2024 Financial Results on September 12, 2024

RH Reports Second Quarter Fiscal 2024 Results

RH to Report Second Quarter Fiscal 2024 Financial Results on September 12, 2024

RH Reports First Quarter Fiscal 2024 Results

Shares of retail and consumer discretionary stocks are trading higher following a rise in June retail sales, indicating continued consumer spending.

10 Consumer Discretionary Stocks Whale Activity In Today's Session

(RH) - Analyzing RH's Short Interest

$RH FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

FDA Approval for DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

$RH Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

RH downgraded by Exane BNP Paribas with a new price target

RH upgraded by Wedbush with a new price target

Stifel initiated coverage on RH with a new price target

Recent Analyst Ratings for
$RH

$RH
SEC Filings

$RH
Insider Trading

$RH
Insider Purchases

$RH
Large Ownership Changes

$RH
Leadership Updates

$RH
Press Releases

$RH
Financials

$RH
Market Insights

$RH
FDA approvals

$RH
Analyst Ratings